Podcast Episodes
Back to Search
Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Un…
1 year, 6 months ago
Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2
Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeut…
1 year, 6 months ago
Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech
Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the wo…
1 year, 6 months ago
Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines
Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partn…
1 year, 6 months ago
Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it
He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylati…
1 year, 6 months ago
A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)
Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery r…
1 year, 6 months ago
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Struct…
1 year, 6 months ago
On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science
Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vect…
1 year, 6 months ago
Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL
CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, a…
1 year, 6 months ago
Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them
Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug the company h…
1 year, 6 months ago